Diseases /
Therapy-Related Myeloid Neoplasm
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: Acute myeloid leukemias, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms arising as a result of the mutagenic effect of chemotherapy agents and/or radiation that are used for the treatment of neoplastic or non-neoplastic disorders. [1]
Therapy-related myeloid neoplasms most frequently harbor alterations in TP53, DNMT3A, TET2, ASXL1, and SRSF2 [2].
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, DNMT3A Mutation, and TP53 Exon 5 Mutation are the most common alterations in therapy-related myeloid neoplasm [2].
Clinical Trials
Significant Genes in Therapy-Related Myeloid Neoplasm
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.